###### Key messages

What is already known about this subject?
=========================================

-   The deleterious effect of active smoking is well documented, however, limited and conflicting literature is found regarding the effect of passive smoking both on the risk of MI and on the mechanism through which it conveys this effect.

What does this study add?
=========================

-   This study confirms the deleterious effect of active smoking on the risk of myocardial infarction (MI) along with its effect on inflammation and lipid profile. We also report changes in the lipid profile with years from smoking cessation. Passive smoking was identified as a strong risk factor of MI, with individuals exposed to passive smoking in a home setting being more at risk than those exposed in a public setting. At least part of the increased risk of MI associated with passive smoke exposure may be explained by its adverse effect on the lipid profile.

How might this impact on clinical practice?
===========================================

-   Programmes to increase awareness on the risk of MI posed by passive smoking should be set up. Laws banning smoking in public, including workplaces, should be established in countries where smoking is still allowed in public spaces and enforced in countries where legislation is already in place. Smoking cessation should be encouraged, as at least some of the pathological effects of smoking are reversible.

Introduction {#s1}
============

Smoking, a known risk factor for myocardial infarction (MI),[@R1] influences various mechanisms, which may accelerate atherogenesis. Active smoking has been associated with endothelial dysfunction,[@R2] an atherogenic lipid profile including lower levels of high-density lipoprotein (HDL) cholesterol[@R3] and with adverse effects on blood coagulability, including increased fibrinogen levels and platelet aggregation.[@R4] Less literature is found on the effects of exposure to passive smoking on the risk of MI. Few of these studies differentiated between exposure at home and in public spaces while taking into account duration of exposure and the effect of potential confounding factors.[@R6] In addition, limited and conflicting literature is available on the mechanisms that lead to the benefits of smoking cessation on the risk of MI and the increased risk associated with passive smoking.[@R9]

The Maltese Acute Myocardial Infarction (MAMI) Study is a case--control study on the Maltese population, which includes population controls. The influence of active smoking, passive smoking and smoking cessation on the risk of MI was investigated as part of this study, together with the effect on inflammation and lipid profile in control subjects.

Methods {#s2}
=======

Study design {#s2a}
------------

MI was defined according to the guidelines issued by the Joint European Society of Cardiology/American College of Cardiology committee.[@R11] Research subjects consisted of 423 consecutive patients admitted with a first MI to Mater Dei Hospital or Gozo General Hospital, Malta, between June 2011 and April 2013 and 465 population controls, all of third-generation Maltese descent. The maximum age of cases was 70 years for men and 75 years for women. Cases were seen twice during the study, once at the time of hospital admission and at least 6 months later at a follow-up visit. Population controls were recruited from the general population through a random list of addresses generated by the National Statistics office. A postal invitation was sent followed by a telephone invitation. Controls with a history of MI, percutaneous coronary intervention or coronary bypass surgery or ECG evidence of a previous or silent MI or of left bundle branch block were excluded from the study. The population control group was frequency matched to cases on sex and 10-year age groups.

Data collection {#s2b}
---------------

Data on conventional risk factors for MI, including age, sex, smoking (both active and passive), alcohol consumption, diabetes mellitus, hypertension, hypercholesterolaemia and other potential risk factors were collected through several sources. These included an extensive interviewer-led questionnaire, physical measurements, including weight, height and waist and hip circumference and morning fasting blood samples on which various biochemical tests were performed. Questionnaire data on 29 cases was not available. Body mass index (BMI) (kg/m^2^) was calculated.[@R12] Current active smokers were those individuals who reported to smoke or use tobacco-containing products. Ex-smokers were those who reported past smoking while non-smokers were individuals who did not report to smoke ever. Both current and past smokers were asked to indicate the average number of cigarettes smoked per day, the age at which they started smoking and in case of ex-smokers the age at which they stopped smoking. Pack-years were calculated by multiplying the number of cigarettes smoked per day by the duration of smoking. Years from smoking cessation were calculated by subtracting the age of quitting smoking from the age at which they started smoking. Individuals exposed to passive smoking were those who reported to currently live with an active smoker/s who smoke/s indoors near them and/or to be exposed to passive smoking in enclosed public spaces including at work.

Blood processing and biochemical tests {#s2c}
--------------------------------------

Lipid profile, haemoglobin A1c (HbA1c) and high-sensitivity C reactive protein (hs-CRP) testing were performed on morning fasting blood samples. Research subjects were instructed to abstain from smoking for at least 12 hours before blood collection to minimise the acute effect of smoking on blood parameters. HbA1c levels were measured on EDTA whole blood using the Bio-Rad Variant II analyser (Bio-Rad Laboratories GmbH, Germany). The lipid profile tests (total cholesterol, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride) were assayed in serum samples on the Roche/Hitachi cobas c311 system (Roche Diagnostics GmbH, Germany). LDL cholesterol was calculated using the Friedewald calculation except when triglyceride levels exceeded 4.52 mmol/L, where the direct LDL cholesterol was assayed. Measurements of serum hs-CRP were determined on the Immulite 2000 immunoassay system (Siemens, USA).

Statistical analysis {#s2d}
--------------------

The differences in median levels of biochemical parameters between active smokers, passive smokers and non-smokers were assessed in control subjects using the Mann-Whitney test. A p value of less than 0.05 was arbitrarily chosen to indicate significance. Results for these comparisons are for men only since on stratification the number of women in certain categories was small. Ex-smokers who had abstained from smoking for less than 1 year were excluded from the analysis of years from smoking cessation. The analysis of passive smoking was restricted to ex-smokers and non-smokers to eliminate confounding by active smoking. The relative risk of MI was calculated using ORs. ORs were adjusted for age (age OR) and for age, sex, regular alcohol consumption, reported hypertension, hypercholesterolaemia, diabetes and BMI (continuous) (aOR). Diabetes and hypercholesterolaemia used for adjustment of these ORs were defined using both the self-reported data from the questionnaire and measurements of HbA1c and total cholesterol, respectively. Individuals with diabetes were defined as having undiagnosed diabetes if they did not report to have diabetes but had elevated HbA1c levels (≥6.5%). Those that reported to have diabetes were divided into uncontrolled diabetics if they had elevated HbA1c levels (≥6.5%) and controlled diabetics if they had normal HbA1c levels (\<6.5%). Individuals who did not report having diabetes and had normal HbA1c levels (\<6.5%) were defined as non-diabetics. Undiagnosed hypercholesterolaemia was deemed present in individuals who did not report suffering from hypercholesterolaemia but had high total cholesterol levels (≥5.0 mmol/L). Individuals with self-reported hypercholesterolaemia were either uncontrolled if their total cholesterol levels were ≥5.0 mmol/L or controlled if their total cholesterol levels were \<5.0 mmol/L. Those who did not report to have hypercholesterolaemia and had total cholesterol levels\<5.0 mmol/L were defined as non-hypercholesterolaemics. The 95% CI was calculated from the logistic regression model. All statistical analyses were performed using SPSS V.21.

Ethical considerations {#s2e}
----------------------

This study was approved by the research ethics committee of the University of Malta (reference number MD 32/2010). Written informed consent was obtained from all individual participants included in the study.

Role of the funding source {#s2f}
--------------------------

The funding sources played no role in the study design, recruitment of research subjects, analysis and interpretation of the data or in the writing and submission of this paper for publication.

Results {#s3}
=======

Characteristics of the MAMI Study cases and population controls are presented in [table 1](#T1){ref-type="table"}. Cardiovascular risk factors were more prevalent in cases with MI compared with controls.

###### 

Characteristics of the MAMI Study participants

                                         Cases with MI\* n=394   Controls n=465
  -------------------------------------- ----------------------- ----------------
  Men (%)                                316 (80.2)              327 (70.3)
  Age years, mean (range)                59 (30--75)             55 (20--77)
  Smokers, N (%)                         146 (37.1)              105 (22.6)
  Ex-smokers, N (%)                      145 (36.8)              161 (34.6)
  Regular alcohol drinkers† (%)          232 (58.9)              311 (66.9)
  Reported diabetes (%)                  110 (28.2)              53 (11.9)
  Reported hypertension (%)              184 (47.2)              160 (35.6)
  Reported hypercholesterolaemia (%)     179 (47.0)              160 (36.9)
  Overweight (BMI 25--30 kg/m^2^)‡ (%)   136 (41.7)              197 (42.6)
  Obese (BMI\>30 kg/m^2^)‡ (%)           149 (45.7)              173 (37.4)

\*A total of 423 cases gave consent to participate in the study, however, 29 cases did not complete their admission questionnaire so questionnaire data about them is missing.

†Regular alcohol drinkers were defined as research subjects who consumed at least one unit of alcoholic beverage, including beer, wine and spirits, per week in a year.

‡BMI cut-offs were as defined by WHO.

BMI, body mass index; MAMI, Maltese Acute Myocardial Infarction; MI, myocardial infarction.

Risk of MI associated with active and passive smoking {#s3a}
-----------------------------------------------------

Active smoking was a risk factor for MI, with current smokers having a 2.7-fold (95% CI 1.7 to 4.2) increased risk of MI compared with non-smokers. This risk decreased to 1.6-fold (95% CI 1.0 to 2.4) among ex-smokers (aORs, [table 2A](#T2){ref-type="table"}). The risk of MI due to active smoking was dependent on the years of smoking and the number of cigarettes smoked. While less than 10 pack-years were not associated with a risk of MI, a higher number of pack-years increased this risk, reaching a 6.9-fold (95% CI 3.7 to 12.8) increased risk for smokers with more than 30 pack-years ([table 2B](#T2){ref-type="table"}).

###### 

Risk of MI in relation to (A) smoking and (B) pack-years

  \(A\) Smoking status                                                
  ---------------------- ------------ ------------ ------------------ ------------------
  Current smokers        146 (37.1)   105 (22.6)   3.1 (2.2 to 4.5)   2.7 (1.7 to 4.2)
  Ex-smokers             145 (36.8)   161 (34.6)   1.7 (1.2 to 2.4)   1.6 (1.0 to 2.4)
  Non-smokers            103 (26.1)   199 (42.8)   1.0                1.0

  \(B\) Pack-years\* (analysis among current smokers only)                                                 
  ---------------------------------------------------------- ------------ ------------ ------------------- -------------------
  \>30 pack-years                                            103 (44.6)   29 (10.2)    7.6 (4.7 to 12.4)   6.9 (3.7 to 12.8)
  10--30 pack-years                                          17 (7.4)     19 (6.7)     2.3 (1.1 to 4.8)    1.9 (0.8 to 4.7)
  \<10 pack-years                                            8 (3.5)      37 (13.0)    0.6 (0.3 to 1.5)    0.5 (0.2 to 1.6)
  Non-smokers                                                103 (44.6)   199 (70.1)   1.0                 1.0

ORs were adjusted for age (age OR) and for age, sex, regular alcohol consumption, reported hypertension, hypercholesterolaemia, diabetes and BMI (aOR).

\*Among current smokers, 18 cases and 20 controls did not specify the number of cigarettes smoked and so were left out of this analysis.

aOR, adjusted OR; BMI, body mass index.

Passive smoking, reported in 69.2% of non-smoker and ex-smoker population controls, also increased the risk of MI. Ex-smokers and non-smokers exposed to passive smoking both at home and in public had a 3.2-fold (95% CI 1.7 to 6.3) increased risk of MI ([table 3A](#T3){ref-type="table"}). Exposure to passive smoking solely in a home setting gave a higher OR (aOR 2.0 (95% CI 0.7 to 5.6)) than exposure to passive smoking solely in a public setting (aOR 1.2 (95% CI 0.7 to 2.0), such as at work, in restaurants and bars ([table 3A](#T3){ref-type="table"}). These aORs were similar even after excluding ex-smokers who had abstained from smoking for less than 15 years (see online [supplementary table S1](#SP1){ref-type="supplementary-material"}). The lower aOR observed for passive smoke exposure in a public setting was not due to the modifying effect of alcohol consumption which often accompanies passive smoking in public since the aOR for public passive smoking among regular alcohol drinkers and that among non-regular alcohol drinkers are both low (aOR 0.7 (95% CI 0.4 to 1.4) and 0.9 (95% CI 0.4 to 1.8), respectively). The risk of MI associated with exposure to passive smoke at home was elevated irrespective of duration of exposure, while the OR for passive smoking in a public setting was elevated only if exposure was greater than 1 hour per day ([table 3B](#T3){ref-type="table"}).
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###### 

Risk of MI among non-smokers and ex-smokers in relation to (A) passive smoking in a home or public setting and (B) with duration of passive smoke exposure in the different settings

  Among non-smokers and ex-smokers only                                                              
  ----------------------------------------------------- ------------ ------------ ------------------ ------------------
  Exposure to passive smoking at home and in public     43 (17.3)    37 (10.3)    1.9 (1.1 to 3.3)   3.2 (1.7 to 6.3)
  Exposure to passive smoking only at home              12 (4.8)     10 (2.8)     1.7 (0.7 to 4.3)   2.0 (0.7 to 5.6)
  Exposure to passive smoking only in public settings   122 (49.2)   202 (56.1)   1.0 (0.7 to 1.4)   1.2 (0.7 to 2.0)
  Not exposed to passive smoking                        71 (28.6)    111 (30.8)   1.0                1.0

  \(B\) Risk with duration of passive smoke exposure                                              
  ---------------------------------------------------- ------------ ------------ ---------------- -------------------
  Duration of home exposure                                                                       
  \>5 hours/day                                        3 (1.2)      3 (0.8)      1.9 (0.4--9.8)   2.6 (0.4 to 15.1)
  1--5 hours/day                                       19 (7.7)     18 (5.0)     1.7 (0.9--3.5)   2.1 (1.0 to 4.6)
  \<1 hour/day                                         33 (13.3)    26 (7.2)     2.0 (1.1--3.4)   2.9 (1.5 to 5.6)
  Not exposure to passive smoking at home              193 (77.8)   313 (86.9)   1.0              1.0
  Duration of passive smoking in public                                                           
  \>5 hours/day                                        32 (12.9)    35 (9.7)     1.3 (0.7--2.2)   1.6 (0.8 to 3.1)
  1--5 hours/day                                       72 (29.0)    95 (26.4)    1.2 (0.8--1.8)   1.6 (0.9 to 2.6)
  \<1 hour/day                                         61 (24.6)    109 (30.3)   0.9 (0.6--1.4)   1.2 (0.7 to 2.0)
  Not exposure to passive smoking in public            83 (33.5)    121 (33.6)   1.0              1.0

ORs were adjusted for age (age OR) and for age, sex, regular alcohol consumption, reported hypertension, hypercholesterolaemia, diabetes and BMI (aOR).

\*9 cases did not specify exposure to passive smoking in the questionnaire and so were left out of this analysis.

aOR, adjusted OR; BMI body mass index.

The effect of active smoking on inflammation and lipid profile {#s3b}
--------------------------------------------------------------

Among male controls, current smokers had higher levels of hs-CRP when compared with non-smokers (median 2.05 mg/L vs 1.28 mg/L, respectively, p value \<0.05), while ex-smokers had intermediate hs-CRP levels between current smokers and non-smokers (median 1.69 mg/L). Current smokers had higher fasting triglyceride levels and total cholesterol:HDL cholesterol ratio, and lower HDL cholesterol compared with non-smokers. Ex-smokers had a lipid profile similar to that of non-smokers, with the exception of serum triglyceride levels, which were higher than those found in non-smokers (1.29 mmol/L vs 1.07 mmol/L, p value \<0.05) ([table 4A](#T4){ref-type="table"}).

###### 

Mean age and median levels and interquartile ranges of biochemical parameters and BMI in male controls by (A) smoking status, (B) pack-years and (C) passive smoke exposure among non-smokers and ex-smokers who have abstained from smoking for \>15 years

  \(A\) Smoking status                                                         
  ------------------------------ ----------------------- --------------------- -------------------
  Age (years), mean (range)      53 (23--70)             59 (20--73)           53 (20--70)
  Hs-CRP (mg/L)                  2.05 (0.83--4.21)\*     1.69 (0.78--3.00)     1.28 (0.64--2.53)
  Total cholesterol (mmol/L)     5.38 (4.80--6.05)       5.48 (4.71--6.13)     5.25 (4.69--5.83)
  LDL cholesterol (mmol/L)       3.44 (2.85--4.04)       3.42 (2.68--4.11)     3.33 (2.81--3.86)
  HDL cholesterol (mmol/L)       1.20 (1.08--1.42)\*     1.35 (1.12--1.61)     1.35 (1.16--1.54)
  Triglycerides (mmol/L)         1.46 (1.06--1.88)\*\*   1.29 (0.88--1.86)\*   1.07 (0.75--1.55)
  Total cholesterol: HDL         4.44 (3.49--5.22)\*     3.96 (3.26--4.95)     3.88 (3.20--4.62)
  Non-HDL cholesterol (mmol/L)   4.19 (3.39--4.86)       4.09 (3.24--4.83)     3.91 (3.24--4.50)
  BMI (kg/m2)                    28.4 (25.0--32.0)       29.1 (27.2--32.2)     28.1 (25.8--32.2)

  \(B\) Pack-years†                                                                                  
  ------------------------------ ----------------------- ----------------------- ------------------- -------------------
  Age (years), mean (range)      59 (47-70)\*            53 (34--69)             44 (23-68)\*        53 (20--70)
  Hs-CRP (mg/L)                  3.14 (1.46--4.29)\*\*   2.53 (1.89--4.03)\*\*   0.82 (0.53--1.86)   1.28 (0.64--2.53)
  Total cholesterol (mmol/L)     5.78 (5.06--6.01)\*     5.02 (4.74--6.98)       5.14 (4.41--5.85)   5.25 (4.69--5.83)
  LDL cholesterol (mmol/L)       3.79 (3.10--3.98)\*     3.21 (3.03--4.59)       3.03 (2.51--3.75)   3.33 (2.81--3.86)
  HDL cholesterol (mmol/L)       1.20 (0.96--1.44)\*     1.19 (1.08--1.27)\*     1.25 (1.16--1.56)   1.35 (1.16--1.54)
  Triglycerides (mmol/L)         1.78 (1.26--2.27)\*\*   1.63 (1.13--2.04)\*\*   1.15 (0.79--1.65)   1.07 (0.75--1.55)
  Total cholesterol: HDL         4.98 (3.76--6.05)\*\*   4.34 (3.89--5.59)\*     3.78 (3.24--4.77)   3.88 (3.20--4.62)
  Non-HDL-cholesterol (mmol/L)   4.50 (3.99--4.86)\*\*   3.99 (3.47--5.73)       3.68 (3.13--4.54)   3.91 (3.24--4.50)
  BMI (kg/m2)                    27.7 (24.8--31.5)       30.0 (25.3--36.3)       28.2 (24.3--31.8)   28.1 (25.8--32.2)

  \(C\) Exposure to passive smoking in non-smokers and ex-smokers                         
  ----------------------------------------------------------------- --------------------- -------------------
  Age (years), mean (range)                                         59 (43--70)           54 (20--71)
  Hs-CRP (mg/L)                                                     1.20 (0.69--3.02)     1.33 (0.72--2.34)
  Total cholesterol (mmol/L)                                        5.73 (4.91--6.57)\*   5.23 (4.40--5.77)
  LDL cholesterol (mmol/L)                                          3.37 (2.33--4.41)     3.17 (2.58--3.72)
  HDL cholesterol (mmol/L)                                          1.35 (1.18--1.58)     1.45 (1.22--1.69)
  Triglycerides (mmol/L)                                            1.50 (0.99--2.40)\*   1.03 (0.78--1.40)
  Total cholesterol: HDL                                            4.23 (3.34--4.93)\*   3.61 (2.93--4.03)
  Non-HDL-cholesterol (mmol/L)                                      4.36 (3.39--5.18)\*   3.70 (2.98--4.33)
  BMI (kg/m^2^)                                                     29.8 (27.0--32.6)     28.7 (26.1--32.1)

The p values, calculated according to the two-tailed Mann-Whitney tests, compare that category with non-smokers for (A) and (B) and with the not exposed for (C).

\*p\<0.05; \*\*p\<0.01.

†16 male smoker controls did not specify the number of cigarettes smoked and were thus excluded from this analysis.

BMI. body mass index; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein.

The increased risk of MI with a higher number of pack-years was reflected by higher levels of hs-CRP levels, total cholesterol, LDL cholesterol, triglycerides, non-HDL cholesterol and total cholesterol to HDL cholesterol ratio. No changes in BMI were evident with increasing pack-years ([table 4B](#T4){ref-type="table"}).

Effect of passive smoking on inflammation and lipid profile {#s3c}
-----------------------------------------------------------

Among male controls, levels of total cholesterol, triglycerides, total cholesterol to HDL cholesterol ratio and non-HDL cholesterol were higher in non-smokers and ex-smokers exposed to passive smoking at home and in public settings than among those not exposed to passive smoking ([table 4C](#T4){ref-type="table"}). These differences were observed even after excluding ex-smokers who had abstained from smoking for less than 15 years to eliminate any residual effect of past active smoking on the lipid profile (data not shown). No differences in hs-CRP levels were observed between those exposed to passive smoking and those not exposed. Any difference in the impact of home and public passive smoke exposure on inflammation and lipid metabolism could not be investigated due to the small number of male controls exposed to passive smoking solely at home.

Impact of smoking cessation on biochemical parameters and risk of MI {#s3d}
--------------------------------------------------------------------

The risk of MI was 2.5-fold (95% CI 1.0 to 5.3) for those who stopped smoking 1 to 4 years earlier. Ex-smokers having abstained from smoking for 5 years or more showed no increased risk of MI ([table 5A](#T5){ref-type="table"}). Further adjustment for passive smoke exposure along with the conventional risk factors of MI did not materially change the ORs. No considerable differences were observed in hs-CRP levels with increasing years of smoking cessation.

###### 

Risk of MI with (A) increasing years from smoking cessation and (B) median levels and interquartile ranges of biochemical parameters, BMI and mean age with years from smoking cessation among male controls

  \(A\) Risk of MI with years from smoking cessation                                                
  ---------------------------------------------------- ------------ ------------ ------------------ ------------------
  1--4 years                                           22 (11.0)    19 (5.3)     2.9 (1.5 to 5.9)   2.5 (1.0 to 5.3)
  5--10 years                                          12 (6.0)     21 (5.9)     1.2 (0.5 to 2.5)   1.0 (0.4 to 2.6)
  11--15 years                                         13 (6.5)     25 (7.0)     1.0 (0.5 to 2.1)   1.0 (0.4 to 2.3)
  \>15 years                                           50 (25.0)    92 (25.8)    0.9 (0.6 to 1.3)   0.8 (0.5 to 1.3)
  Non-smokers                                          103 (51.5)   199 (55.9)   1.0                1.0

  **(b) Years from smoking cessation**                                                                                             
  -------------------------------------- --------------------- ----------------------- ----------------------- ------------------- ------------------
  Age (years), mean (range)              54 (26--68)           57 (28--70)             58 (32--70)\*           62(40--73)\*        53 (20-70)
  Hs-CRP (mg/L)                          1.77 (1.44--4.54)     1.56 (0.72--2.81)       2.19 (0.76--4.30)       1.68 (0.78--2.74)   1.28 (0.64-2.53)
  Total cholesterol (mmol/L)             5.37 (4.43--6.28)     5.78 (5.07--6.37)       5.97 (5.26--6.32)\*     5.41 (4.55--5.94)   5.25 (4.69-5.83)
  LDL-cholesterol (mmol/L)               3.41 (2.42--4.20)     3.79 (2.91--4.04)       3.75 (3.12--4.24)       3.22 (2.55--4.09)   3.33 (2.81-3.86)
  HDL-cholesterol (mmol/L)               1.31 (1.11--1.47)     1.31 (1.06--1.58)       1.48 (1.11--1.65)       1.34 (1.12--1.63)   1.35 (1.16-1.54)
  Triglycerides (mmol/L)                 1.70 (1.04--2.33)\*   1.74 (1.20--2.36)\*\*   1.52 (1.41--2.09)\*\*   1.07 (0.84--1.60)   1.07 (0.75-1.55)
  Total cholesterol: HDL                 4.16 (3.42--4.79)     3.96 (3.06--5.50)       3.75 (3.12--4.24)       3.87 (3.11--4.70)   3.88 (3.20-4.62)
  Non-HDL-chol (mmol/L)                  3.88 (3.28--4.95)     4.40 (3.18--5.28)       4.43 (3.95--5.05)\*     3.86 (3.07--4.81)   3.91 (3.24-4.50)
  BMI (kg/m2)                            30.1 (28.1--35.1)\*   30.5 (27.8--37.2)\*\*   28.7 (26.8--31.2)       28.7 (26.6--31.6)   28.1 (25.8-32.2)

Levels among non-smokers are also presented.

ORs were adjusted for age (age OR) and for age, sex, regular alcohol consumption, reported hypertension, hypercholesterolaemia, diabetes and BMI (AdjOR).

\*p \<0.05; \*\*p\<0.01.

†Ex-smoker cases and controls who stopped smoking less than a year ago were not included in this analysis. The p values, calculated according to the two-tailed Mann-Whitney tests, compare that category with non-smokers.

aOR, adjusted OR\' BMI, body mass index; MI myocardial infarction.

Serum triglyceride levels decreased with years from smoking cessation, with male controls who had stopped smoking more than 15 years previously having similar levels as non-smokers ([table 5B](#T5){ref-type="table"}).

Discussion {#s4}
==========

Both active and passive smoking are risk factors for MI. The risk of MI drastically increases with smoking intensity and decreases after 5 years from smoking cessation. The increased risk of MI associated with smoking was reflected by a higher inflammatory state (as indicated by hs-CRP levels) and altered lipid profile, with elevation of triglyceride levels and decreased HDL cholesterol levels being the most pronounced changes.

Passive smoking emerged as a strong risk factor for MI (aOR 3.2 (95% CI 1.7 to 6.3)). In this study, passive smoke exposure was associated with higher levels of triglycerides, total cholesterol: HDL-cholesterol ratio and non-HDL-cholesterol, which may be mediating at least part of the risk of MI associated with passive smoking. Though there are few studies on the effects of passive smoking on the lipid profile, our results are concordant with those from two other studies,[@R13] thus strengthening the evidence of a true effect.

The effect of passive smoking was strong in a home setting. A high risk of acute MI has been previously observed among individuals who lived with a smoking spouse or had children who smoked.[@R6] Although it has been suggested that drinking often accompanied passive smoke exposure in public settings,[@R15] the difference between the risks in the two settings analysed was not due to the effect of alcohol consumption in a public setting, as the risk of MI due to public passive smoke exposure was low in both alcohol drinkers and non-alcohol drinkers.

We cannot exclude under-reporting of active smoking. This would lead to misclassification of active smokers as non-smokers. In addition, despite clearly specifying during the interview that exposure to passive smoking in public was only valid if it occurred in a closed environment, it could not be excluded that individuals also reported exposure to passive smoking that occurred in open public spaces. Individuals who reported to have been exposed to public passive smoking may have been exposed years ago and the deleterious effect may have subsided. These limitations might explain the observed discrepancy in the risk of MI associated with passive smoke exposure between a home and public setting. If smokers are more likely to live with a smoker, under-reporting of active smoking could result in an excessive misclassification of active smokers as passive smokers resulting in a higher risk for passive smoking at home. Furthermore, recall bias might have occurred, since cases with MI might be less likely to report that they smoke when compared with controls. In that case, the actual risk of MI for active smokers might even have been higher.

Conflicting literature still exists on the dose--response relation between passive smoke exposure and risk of MI.[@R16] In this study, the strong risk of MI due to passive smoke exposure at home was independent of the duration of exposure and already had an effect with very short exposure time. While passive smoke exposure in a public setting for a short duration did not increase the risk of MI, elevated aORs were observed among individuals exposed for a longer duration.

Observations on both the risk of MI due to active smoking and effects of smoking on inflammation and lipid profile are similar to previous findings, where the increased predisposition for MI among smokers has been associated with an abnormal lipid profile.[@R18]

Concordant with our findings, the dose--response increase in risk of MI with pack-years was reported in the INTERHEART Study where a strong and graded relation was found between the number of cigarettes smoked and risk of MI.[@R20] This risk was reflected by an increase in markers of inflammation.[@R21] A higher number of pack-years was associated with elevated levels of total cholesterol, triglycerides and LDL cholesterol and a simultaneous reduction in HDL cholesterol levels. Such observations confirm findings of other authors who reported a direct relationship between increasing pack-years and abnormal lipid profiles.[@R22]

Smoking cessation was associated with a decreased risk of MI. The risk of MI due to past smoking was no longer evident 5 years after smoking cessation. Other authors reported similar beneficial effect of smoking cessation, including reduced risk of MI, stroke, cardiovascular disease and total mortality.[@R24] However, conflicting literature still exits about the impact of smoking cessation on the lipid profile.[@R9] In the current study, at least part of the benefit of smoking cessation was attributed to improved lipid profile. Triglyceride levels decreased with increasing years from smoking cessation, with ex-smokers who have abstained from smoking for more than 15 years having similar levels as non-smokers.

In conclusion, both active and passive smoking conveyed an equally deleterious effect on the risk of MI. A dose--response increase in risk was observed with increasing pack-years. At least part of the risk of MI due to active smoking was mediated through a higher inflammatory state, while both active and passive smoking were associated with an altered lipid profile. Programmes to increase awareness on the risk of MI posed by passive smoking should be set up. Laws banning smoking in public, including workplaces, should be established in countries where smoking is still allowed in public spaces and enforced in countries where legislation isalready in place. Smoking cessation should be encouraged, as at least some of the pathological effects of smoking are reversible. Given the high prevalence of both active and passive smoking and their strong effect on the risk of MI, both should be considered when studying the effect of other lifestyle, environmental and genetic factors.
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